Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Veru (VERU) Stock Price
News stories about Veru (NASDAQ:VERU) have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veru earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.1939089470729 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Veru (VERU) Given a $5.00 Price Target at HC Wainwright (americanbankingnews.com)
- ETFs with exposure to Veru, Inc. : December 14, 2017 (finance.yahoo.com)
- Future of the Global Sexual Wellness Market – Growth, Latest Trend & Forecast 2022 (newsient.com)
- Veru Acquires Novel Proprietary Formulation for Overactive Bladder (finance.yahoo.com)
Veru (NASDAQ:VERU) opened at $1.24 on Friday. Veru has a fifty-two week low of $0.90 and a fifty-two week high of $3.00.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Veru (VERU) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-veru-veru-stock-price/1767599.html.
Veru Company Profile
Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.